All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
CARTITUDE-1 study: Are responses with cilta-cel deep and durable?
Video series
ASH 2020 | Novel therapies for RRMM
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, about the CARTITUDE-1 study. We asked, Are responses with ciltacabtagene autoleucel (cilta-cel) deep and durable?
Madduri discusses the preliminary data from the CARTITUDE-1 study evaluating cilta-cel in patients with relapsed/refractory multiple myeloma.
Video series
ASH 2020 | Novel therapies for RRMM
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox